Solèr M, Perruchoud A P
Abteilung für Pneumologie, Kantonsspital Basel.
Schweiz Med Wochenschr. 1993 Feb 6;123(5):165-9.
Reports on an increase in asthma deaths in New Zealand in the late 1970s have led to a series of case-control studies aimed at identifying possible reasons for increased asthma mortality. The most intriguing finding was association of the use of beta 2-agonists as metered dose inhalers with death from asthma. Although these epidemiologic studies cannot definitely identify the cause of the increased asthma mortality, they have stimulated widespread discussion and reevaluation of therapeutic strategies. The reliability of the mortality data and the role of beta 2-agonists in this context are discussed.
20世纪70年代末，有关新西兰哮喘死亡人数增加的报告引发了一系列病例对照研究，旨在找出哮喘死亡率上升的可能原因。最引人关注的发现是，使用β2受体激动剂定量吸入器与哮喘死亡之间存在关联。尽管这些流行病学研究无法确切确定哮喘死亡率上升的原因，但它们引发了广泛的讨论，并促使人们对治疗策略进行重新评估。本文讨论了死亡率数据的可靠性以及β2受体激动剂在这一背景下的作用。
